Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Your donations help support people living with type 1 diabetes today and fund the best treatment and cure research, no matter where in the world it takes place.
The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.
Join our Virtual Triathlon Challenge and swim, cycle and run while raising money to fund Breakthrough T1D’s life-changing type 1 research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
JDRF has now rebranded to Breakthrough T1D. Our name has changed, our mission has not.
Home > News & events > News > Report reveals Covid pandemic’s impact on people with type 1 diabetes
A new report from JDRF finds almost one in two UK adults with type 1 diabetes (47%) believe the Covid pandemic – and the disruption to NHS diabetes services it triggered – is likely to have a long-term impact on their life with the condition.
JDRF surveyed more than 1,000 people living with type 1 diabetes, or caring for a child living with it, to reveal their experiences through the upheavals of the Covid pandemic. The findings of the report reveal the impact of the withdrawal and repurposing of many NHS diabetes services on people with type 1. JDRF’s report, entitled Covid and Beyond: Confronting the Unequal Access to Type 1 Diabetes Healthcare sets out a series of recommendations, anchored in the needs of people living with type 1.
The survey found that half of adults with type 1 said they felt unsupported at times during the Covid crisis, with 63% of adults reporting they were unable to access their normal level of healthcare support. This is significantly higher than adults living with other health conditions, such as cancer or heart problems.
The study highlights the experiences of those most likely to be hardest hit by the effect of the pandemic: through qualitative interviews with people with type 1 in lower income households, ethnic minority communities and people living with type 1 as well as other long term health conditions. The report found that there was a range and variation of care, according to particular local specialist and primary care service provision.
The report shows that people with access to type 1 wearable medical technologies such as insulin pumps, flash and CGM felt better able to manage their condition during the pandemic.
Recent studies have found that people from socially deprived areas, ethnic minority backgrounds, and older people who were diagnosed longer ago typically have lower usage of type 1 diabetes technology, making them potentially worse off throughout the pandemic.
A further finding identified that adults living with type 1 reported greater disruption in their diabetes health care services than parents with children living with the condition.
Adrian Long, of Lancashire, who lives with type 1 diabetes, feels that his wearable medical technologies and education in type 1 diabetes self-management meant that he was better prepared during the crisis, in the absence of NHS diabetes support. Adrian says he did benefit from a “seamless” upgrade to his flash glucose sensor device during the pandemic, thanks to a “very supportive GP.”
Adrian Long, who lives with type 1 diabetes
But speaking of his type 1 diabetes NHS care, he said: “I have not seen my hospital team in almost two years, and my only interactions have been by phone – not even video calls. Likewise I have also not seen my GP for an annual diabetes review in almost two years, but again, have spoken by phone instead. I would very much hope that my next scheduled reviews, due at the end of this year, will be face to face, not least for those overdue foot and injection site checks.”
The report’s recommendations are:
UK Chief Executive of JDRF, Karen Addington, said: “Our recommendations point the way for an NHS that can build back an integrated type 1 diabetes service, that optimises quality of care and support, as well as positive outcomes for those living with the condition. People affected by type 1 diabetes hold expertise. Such expertise is valuable for clinical adaptation as we move beyond Covid.”
She added: “Despite the major disruption to type 1 diabetes healthcare, 58% of adults living with type 1 diabetes felt the NHS had done its best to support them during the pandemic. This reflects an admiration of NHS staff and their efforts throughout the pandemic that we at JDRF share.
“JDRF is committed to working with its partners in the NHS, government and other stakeholders on the adoption of the recommendations in our report, to help guide the rebuilding of NHS services and support.”
Read the full Covid and Beyond report.
Our highlights from a year full of breakthroughs in type 1 diabetes research and advocacy.
The framework aims to encourage UK researchers to consider different sexes (biological attributes) and genders (roles, behaviours and identity in society) to address gaps in health data.
Our Access for All report, launched today, highlights how far we’ve come with advancements in diabetes technology, but shows that many people still face barriers when trying to access T1D technology.
New international guidance detailing how to monitor and support people with early-stage type 1 diabetes (T1D) has the potential to reduce the trauma associated with being diagnosed with T1D, enable people to access the latest treatments to delay the need for insulin therapy, and reduce long-term health complications.